CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY

Masamitsu Konno, Hideshi Ishii, Yuichiro Doki, Masaki Mori

研究成果: Contribution to journalArticle

抜粋

Although cancer is a genetic disease, epigenetic alterations are involved in its initiation and progression. Previous studies showed that the introduction of endogenous small-sized, noncoding ribonucleotides including microRNA200c, -302s, and -369 resulted in the induction of cellular reprogramming. MicroRNA200c inhibits the epithelial-mesenchymal transition. MicroRNA302s induces the demethylation of the tumor suppressor gene promoter region, while microRNA369 changes cancer cell metabolism. These three types of microRNA induce cancer cellular reprogramming and modulate malignant phenotypes of human cancer cells. These results suggest that the appropriate delivery of functional small-sized ribonucleotides may be a novel approach to the treatment of human cancer.

元の言語英語
ページ(範囲)357-359
ページ数3
ジャーナルNihon Geka Gakkai zasshi
116
発行部数6
出版物ステータス出版済み - 11 1 2015
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Konno, M., Ishii, H., Doki, Y., & Mori, M. (2015). CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY. Nihon Geka Gakkai zasshi, 116(6), 357-359.